UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat head and neck cancer
Disease control OngoingThis study tests a combination of two drugs—cetuximab and interleukin-12—in people with advanced head and neck cancer that cannot be removed by surgery or has spread. The goal is to find the best dose and see if the combination can shrink tumors. Twenty-three participants are enr…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo aims to boost immune attack on HPV-Driven head and neck cancer
Disease control OngoingThis Phase 3 trial tests whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer. About 252 participants will receive either the combination or pembrolizumab alone. T…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug duo shows promise against tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC